Sequenom Discloses Mishandling of Test Data; Shares Plummet | GenomeWeb

NEW YORK (GenomeWeb News) – Sequenom said Wednesday after the close of the market that it would delay the launch of its SEQureDx Down syndrome test until the third quarter of this year after it discovered that company employees had mishandled R&D test data and results.

"This raises significant concerns regarding the integrity of that data," said Sequenom President and CEO Harry Stylli during a conference call.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.